The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting
1,000 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 Recruiting
87 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
VERDI
Phase NA Recruiting
1,020 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
DP-04
Recruiting
100 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Phase 1/2 Recruiting
51 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
BASECAMP-1
Recruiting
200 enrolled
EXCEED
Phase 1 Recruiting
490 enrolled
SJFAMILY
Recruiting
1,500 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 Recruiting
740 enrolled
iCaRe2
Recruiting
999,999 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
EXoPERT EMERALD Clinical Study
Recruiting
1,400 enrolled
CAMPERR
Recruiting
7,000 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
(CLOCS-2)
Recruiting
2,900 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
220 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
METEOR-CRATR
Phase NA Recruiting
60 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Phase 1/2 Recruiting
300 enrolled
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
15 enrolled
TraveraRTGx
Recruiting
200 enrolled
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Phase 1 Recruiting
429 enrolled
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 Recruiting
21 enrolled
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Phase 1 Recruiting
292 enrolled
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 Recruiting
52 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
PIPAC-NAL-IRI
Phase 1 Recruiting
45 enrolled
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
Recruiting
1,200 enrolled
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
115 enrolled
HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
150 enrolled
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
318 enrolled
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 Recruiting
12 enrolled